Why Idera Pharmaceuticals Soared 20% In September

download Why Idera Pharmaceuticals Soared 20% In September

If you can't read please download the document

  • date post

    14-Jan-2017
  • Category

    Healthcare

  • view

    3.210
  • download

    2

Embed Size (px)

Transcript of Why Idera Pharmaceuticals Soared 20% In September

  • Why Idera Pharmaceuticals Soared 20% In September

  • What:The clinical-stage biotech company is studying two drugs.IMO 8400 for B-cell lymphomas.IMO 9200 for autoimmune disease.Data should be released on IMO 8400 in Q4.Results from its phase 2 Waldenstroms macroglobulinemia trial.Shares jumped 20.1% in September.

  • Idera Pharmaceuticals

  • So what:Under development to treat Waldenstroms and diffuse B-cell lymphoma with an amenable genetic mutation.Could benefit up to 90% of 1,200 new WM cases annually.Could treat up to 30% of the 2,000 new diffuse B-cell lymphoma cases annually.

  • Now what:WM phase 2 data coming this quarter.Mid stage results could be encouraging, but a phase 3 trial still needs to occur.Diffuse B-cell lymphoma data expected next year.Potential therapy for pre-treated patients would be welcome, but too early to gauge whether this one will be a success.

  • Now what continued:Cash totals $106.3 million exiting Q2.Operating expenses totaled $12.8 million last quarter.Expanding trials will increase cash burn in the coming year.High-risk/high-reward play suitable only for aggressive investors.Keep an eye out for upcoming WM data.